CSL Signs 2 Initial Agreements for Coronavirus Vaccine Supply
By David Winning
SYDNEY--CSL Ltd., Australia's largest pharmaceutical company,
said it had signed initial deals for the supply of vaccines against
the novel coronavirus if they successfully complete clinical
CSL said a heads of agreement with the Australian government
covers 51 million doses of a vaccine being developed by the
University of Queensland. Supply could begin around the middle of
next year, the company said.
Production of the vaccine to support late-stage clinical trials
is underway at CSL's biotech manufacturing facilities in
Broadmeadows, a suburb of Melbourne.
CSL said results from pre-clinical and early clinical studies
for the vaccine, known as UQ-CSL V451, are promising. The
University of Queensland is currently undertaking a Phase 1
clinical study to assess the vaccine candidate's safety and
immunogenicity in healthy volunteers.
"Should the Phase 1 study prove to be successful toward the end
of this year, CSL will take full responsibility for the subsequent
Phase 2b/3 clinical trial, which is expected to commence in late
2020," CSL said.
CSL added it has a separate heads of agreement with AstraZeneca
PLC to manufacture around 30 million doses of the AZD1222 vaccine
candidate being developed by Oxford University, with the first
doses scheduled for release early next year if it's successful in
The Australian government will offer funds to support CSL's
ability to manufacture AZD1222, the company added.
"We are pleased that we can produce the AZD1222 without
compromising the production of our core products--influenza
vaccines and plasma and recombinant protein therapies--and provide
a second option for a Covid-19 vaccine candidate to Australia," CSL
Chief Executive Paul Perreault said.
Write to David Winning at firstname.lastname@example.org
(END) Dow Jones Newswires
September 06, 2020 18:51 ET (22:51 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.